Dr Tanya Saraiya from the Medical University of South Carolina recently presented groundbreaking research on addressing underlying trauma among people struggling with opioid use during a Turning Point webinar. Her work reveals the critical intersection between trauma exposure and opioid dependence, highlighting the urgent need for integrated treatment approaches that address both conditions simultaneously.

The research demonstrates that up to 90% of people with opioid use disorder have experienced trauma, with up to 41% meeting criteria for post-traumatic stress disorder (PTSD). Despite these alarming statistics, fewer than 12% of individuals with both conditions receive treatment for their PTSD, creating a significant gap in comprehensive care.

The Connection Between Trauma and Opioid Dependence

Dr Saraiya’s research builds upon compelling evidence demonstrating the unique relationship between trauma exposure and opioid use. An Australian twin study examining 6,000 participants found that twins exposed to childhood sexual abuse had 6.5 times higher odds of developing opioid use disorder in adulthood compared to their non-exposed siblings.

This represents the highest risk ratio amongst all substance use disorders, suggesting that opioids hold particular appeal for individuals with trauma histories. Researchers hypothesise that opioids’ numbing qualities make them especially attractive to those seeking relief from both physical and emotional pain, providing a sedative effect that other substances may not offer.

Further supporting this connection, a 2021 meta-analysis of 62 studies involving 22,000 individuals found the highest rates of childhood maltreatment amongst those with opioid use disorders compared to other substance dependencies. The study documented elevated rates of childhood sexual abuse, physical abuse, emotional abuse, and neglect amongst opioid users.

Traditional Treatment Challenges and Integrated Solutions

Historically, trauma-informed opioid treatment has been hampered by siloed approaches that address trauma and substance use separately. Traditional systems often require individuals to become abstinent from substances before receiving trauma treatment, creating barriers that ultimately prevent recovery.

This approach fails to recognise that substances often serve as coping mechanisms for trauma symptoms. When individuals are required to eliminate their primary coping strategy without adequate replacement support, they face increased vulnerability and reduced likelihood of engaging with treatment services.

The revolutionary concept of integrated treatment emerged as a response to these limitations, offering a “one-stop shop” where individuals can receive simultaneous treatment for both PTSD and substance use disorders. This approach recognises the interconnected nature of these conditions and provides comprehensive support within a single treatment framework.

Developing HOPE: An Innovative Treatment Protocol

Dr Saraiya’s team developed HOPE (Helping Opioid Use Disorder and PTSD with Exposure), an adapted trauma-informed opioid treatment protocol specifically designed for individuals with both conditions. The intervention builds upon existing evidence-based treatments whilst addressing the unique needs of this population.

HOPE incorporates multiple therapeutic approaches, including cognitive behavioural therapy, evidence-based trauma processing techniques, and integration with medications for opioid use disorder. The protocol was developed through extensive consultation with both treatment providers and patients, ensuring it addressed real-world clinical needs and preferences.

Key features of trauma-informed opioid treatment through HOPE include reduced homework requirements, increased session flexibility to accommodate crisis situations, and modified exposure protocols that require fewer traumatic retellings compared to traditional approaches. The treatment consists of 10-12 individual sessions of 60 minutes each, making it more feasible for implementation in standard healthcare settings.

Promising Treatment Outcomes and Retention Rates

Preliminary research on the HOPE protocol demonstrates encouraging results for trauma-informed opioid treatment. In a pilot study involving individuals with both opioid use disorder and PTSD, participants showed significant decreases in PTSD symptoms throughout treatment, with reductions beginning around session four and continuing through follow-up.

The intervention achieved an 83.3% treatment retention rate, representing the highest completion rate documented for any trauma-focused therapy targeting this population. This finding is particularly significant given that traditional integrated treatments typically experience 50% dropout rates.

Participants reported high satisfaction with the treatment approach, with ratings consistently improving throughout the therapy process. Even sessions involving trauma processing, typically the most challenging component, were ultimately viewed positively by participants who recognised their therapeutic value.

Addressing Diagnostic and Screening Challenges

Dr Saraiya’s research also highlights significant challenges in current diagnostic frameworks that may limit access to trauma-informed opioid treatment. The DSM-5 criteria for trauma exposure exclude many experiences commonly reported by individuals with opioid use disorders, including incarceration, emotional abuse, and neglect.

This diagnostic limitation creates barriers for individuals whose most distressing experiences don’t meet formal trauma criteria, potentially excluding them from evidence-based trauma treatments. The research advocates for expanding trauma definitions to include identity-based traumas, systemic traumas, and previously invisible forms of trauma exposure.

Additionally, clinical settings often lack adequate screening tools to identify individuals with both conditions. Research indicates that treatment programmes frequently fail to detect co-occurring PTSD amongst their patients, limiting opportunities for integrated intervention.

The I-PIVOT Toolkit: Enhancing Screening and Safety

Addressing screening limitations, Dr Saraiya’s team developed the I-PIVOT toolkit, a digital assessment tool designed to identify intimate partner violence amongst individuals receiving opioid treatment. This innovation recognises that 90% of patients receiving methadone treatment report experiences of intimate partner violence, yet screening typically occurs only for female-presenting individuals.

The toolkit aims to increase screening comprehensiveness whilst providing safety planning resources and treatment recommendations. By leveraging technology, the system can assess danger levels and provide appropriate referrals to domestic violence services and mental health support.

This approach represents a significant advancement in trauma-informed opioid treatment by addressing one of the most common yet under-detected trauma exposures in this population. The toolkit’s implementation could improve safety outcomes whilst enhancing coordination between opioid treatment programmes and domestic violence services.

Cultural Considerations and Health Disparities

Dr Saraiya’s work emphasises the importance of addressing health disparities within trauma-informed opioid treatment. Research demonstrates that trauma-focused treatments show poorer outcomes for non-Caucasian individuals, despite these populations experiencing higher rates of trauma exposure.

The research attributes these disparities to various factors, including sociopolitical contexts, systemic racism, and cultural barriers within treatment frameworks. Current diagnostic criteria may particularly disadvantage individuals from minoritised communities whose trauma experiences don’t align with traditional definitions.

Addressing these disparities requires trauma-informed opioid treatment approaches that recognise diverse forms of trauma exposure, including race-based trauma, immigration-related stress, and intergenerational trauma effects. Treatment protocols must be adapted to acknowledge and address these broader contextual factors.

Future Directions for Integrated Treatment

Dr Saraiya’s research programme continues expanding understanding of trauma-informed opioid treatment through ongoing randomised controlled trials. Current studies are examining HOPE’s effectiveness compared to medication-only approaches, with preliminary enrollment demonstrating continued interest in integrated treatment options.

The research utilises ecological momentary assessment techniques to understand real-time relationships between trauma symptoms, substance use, and coping abilities. This approach provides detailed insights into how integrated treatment affects daily functioning and symptom management.

Future implementation efforts focus on translating research findings into community clinic settings, ensuring that trauma-informed opioid treatment becomes accessible beyond research environments. This work includes addressing implementation barriers, training requirements, and sustainability factors necessary for widespread adoption.

The development of enhanced screening tools and expanded trauma definitions represents another crucial direction for advancing trauma-informed opioid treatment. By improving identification of individuals who could benefit from integrated approaches, treatment systems can better serve this vulnerable population.

Dr Saraiya’s comprehensive approach to trauma-informed opioid treatment demonstrates the potential for integrated interventions to address complex presentations that have historically challenged traditional treatment systems. Through continued research and implementation efforts, these innovations offer hope for improving outcomes amongst individuals facing the dual challenges of trauma exposure and opioid dependence.

Source: YouTube